There's no sugar-coating it: GlaxoSmithKline (GSK 0.12%) had a pretty rough second quarter. U.S. sales of aging blockbuster Advair dropped by an astounding 19%, and Breo and Anora Ellipta, which have been hailed as potential blockbusters, turned in disappointing sales (5 million pounds each in the U.S.). Watch the video below for a quick take on earnings from Motley Fool health care analysts Michael Douglass and David Williamson.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.